Praxbind approved by FDA to reverse blood thinning effect of Pradaxa

October 18, 2015 6:53 PM

18 0

FDA granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.

Also read: Valeant prices psoriasis treatment at $3,500 per month

Read more

To category page

Loading...